There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Brett Montgomery |
| Institution: | Hoag Memorial Hospital Presbyterian |
| Department: | Pickup Family Neurosciences Institute |
| Country: | |
| Proposed Analysis: | Psychotropic medications are commonly prescribed to patients with dementia and Alzheimer’s disease to assist in moderating disturbances in behavior and mood. This class of medication can also be utilized to treat other common symptoms and abnormal behavior that may be present, including restlessness, agitation, aggression, insomnia, wandering, or a combination of these symptoms (Ellul et al., 2006). There is mounting evidence that there may be a link between cognitive decline and the use of psychotropic medications. Research has shown that exposure to all major classes of psychotropic medications may be associated with a faster rate of cognitive decline as measured by the mini-mental state examination, with several classes of these medications associated with a more rapid increase in dementia severity (Rosenberg et al., 2012). Additionally, long-term antipsychotic use has been associated with a significantly greater cognitive decline and dementia progression (Dyer et al., 2021). The current study seeks to examine the relationship between the use of psychotropic medications on cognitive functioning as measured by an MMSE and/or the CDRS. The aim is to examine the correlation of psychotropic medications on the cognitive decline between individuals that are prescribed psychotropic medications and those that are not, while controlling for other factors that can contribute to a decline in cognitive functioning. |
| Additional Investigators |
